IPOs and Secondaries

IPOs and Secondaries Articles

Byline Bancorp intends to price more than 5 million shares in the range of $19 to $21 apiece in an initial public offering valued up to more than $137 million.
Blue Apron intends to price 30 million shares in the range of $15 to $17 apiece for an initial public offering valued up to more than $586 million.
As many as nine IPOs may hit the public markets this week, led by cable and broadband provider Altice.
Boston Omaha entered the market quietly on Friday in its initial public offering. Shares opened more or less in line with the expected price.
Mersana Therapeutics expects to price its 5 million shares in the range of $14 to $16 apiece in an initial public offering valued up to $92 million.
Tintri intends to price more than 8 million shares in the range of $10.50 to $12.50 for an initial public offering valued up to about $125 million.
Apollo Endosrugery saw its shares slide on Thursday after it was announced that the company would have a secondary offering.
Chemical products maker Venator Materials has filed with the U.S. Securities and Exchange Commission for its initial public offering.
The initial public offering of Saudi Aramco has been delayed, Mattel has slashed its dividend, and are the Federal Reserve's plans for future rate increases flawed?
Boston Omaha expects to price more than 5 million shares in the range of $12 to $14 apiece in an initial public offering valued up to more than $88 million.
Ranger Energy Services has amended its filing with the U.S. Securities and Exchange Commission for its initial public offering.
Frontier Group Holdings has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Altice USA expects to price more than 46 million shares in the range of $27 to $31 apiece for an initial public offering valued up to approximately $1.6 billion.
PQ Group Holdings has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Dova Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).